173 / 260
Note 28.13 Loans
Disclosures pursuant to the Regulation 34(3) read with para A of Schedule V to the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015 read with Section 186(4) of the Companies Act, 2013.
(
`
cr)
Particulars
Purpose
Amount outstanding
as at
Maximum balance
during the year
March
31, 2019
March
31, 2018
2018-19
2017-18
i)
Subsidiary companies:
Atul Bioscience Ltd
Seed funding support as promoters
-
-
-
ǪȦǩǦ
Amal Ltd *
Interest free loan, pursuant to
Board for Industrial and Financial
Reconstruction order
ǪȦǯǨ
7.07
7.07
7.89
* at amortised cost
a) Loans given to employees as per the policy of the Company are not considered.
b) The loanees did not hold any shares in the share capital of the Company.
Note 28.14 Disclosure requirement under MSMED Act, 2006
The Company has certain dues to suppliers (trade and capital) registered under Micro, Small and Medium Enterprises
Development Act, 2006 (‘MSMED Act’). The disclosures pursuant to the said MSMED Act are as follows:
(
`
cr)
Particulars
As at
March 31, 2019
As at
March 31, 2018
Principal amount due to suppliers registered under the MSMED Act and
remaining unpaid as at year end
ǭȦǨǪ
ǪȦǦǬ
Interest due to suppliers registered under the MSMED Act and remaining
unpaid as at year end
0.01
0.02
Principal amounts paid to suppliers registered under the MSMED Act, beyond
the appointed day during the year
1.11
ǧȦǧǪ
Interest paid, other than under Section 16 of MSMED Act, to suppliers
registered under the MSMED Act, beyond the appointed day during the year
-
-
Interest paid, under Section 16 of MSMED Act, to suppliers registered under
the MSMED Act, beyond the appointed day during the year
0.02
0.02
Interest due and payable towards suppliers registered under MSMED Act, for
payments already made
-
-
Further interest remaining due and payable for earlier years
-
-
Note 28.15 Expenditure on Corporate Social Responsibility initiatives
a) Gross amount required to be spent by the Company during the year is
`
7.90 cr
b) Amount spent during the year on:
(
`
cr)
Particulars
Paid Payable
Total
i)
Construction | Acquisition of any asset
-
-
-
ii) On purposes other than (i) above
7.90
-
7.90
171
Standalone
|
Notes to the Financial Statements